Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has reported a 7.2% beneficial ownership stake in Ares Management Corporation's Class A Stock as of December 31, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in Grupo Televisa SAB's common stock.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Bankwell Financial Group, Inc. as of December 31, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 12.5% beneficial ownership of Luxfer Holdings PLC's common stock, totaling 3,333,423 shares as of December 31, 2025.

BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in quantum computing company IonQ, Inc. as of December 31, 2025.

BlackRock, Inc. has reported a beneficial ownership of 6.9% of Embraer S.A.'s common stock, totaling 50,955,237 shares, as of December 31, 2025.

BlackRock, Inc. has reported an 8.6% beneficial ownership stake in BorgWarner Inc. common stock as of December 31, 2025, through a Schedule 13G/A filing.

BlackRock, Inc. has reported a 6.5% beneficial ownership stake in Brazilian Electric Power Co.'s Preferred Class B1 Shares as of December 31, 2025.

BlackRock, Inc. has reported a 6.5% beneficial ownership stake in Kinross Gold Corp., holding 78,955,000 common shares as of December 31, 2025.

BlackRock, Inc. has disclosed an 11.2% beneficial ownership stake in Gates Industrial Corp plc, holding 28,830,770 shares of common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 6.5% beneficial ownership stake in Cogent Biosciences, Inc. as of December 31, 2025.

BlackRock, Inc. has reported an updated beneficial ownership of 9.3% of Camden Property Trust's common stock, holding 9,872,008 shares.

BlackRock, Inc. has reported an 8.4% beneficial ownership stake in Community Healthcare Trust Incorporated, holding 2,396,124 common shares.

BlackRock, Inc. has reported a 6.6% beneficial ownership stake in Oruka Therapeutics, Inc., holding over 3.1 million shares of common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 9.6% beneficial ownership stake in Owens Corning common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.00% beneficial ownership stake in Peoples Bancorp of North Carolina Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in KORU Medical Systems Inc., holding 2,345,369 shares of common stock.

BlackRock, Inc. has reported a 7.1% beneficial ownership stake in RICHTECH ROBOTICS INC.'s Class B Stock, totaling 11,243,953 shares.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Sana Biotechnology Inc., holding 13,643,304 shares of common stock as of December 31, 2025.

BlackRock, Inc. has reported an increased beneficial ownership of 12.6% in Sarepta Therapeutics Inc. common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Savara Inc.'s common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.3% beneficial ownership stake in Shoe Carnival Inc., holding 1,438,037 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.96% passive ownership stake in Spire Global, Inc.'s Class A Stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 12.2% beneficial ownership stake in Sterling Infrastructure, Inc. common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 8.0% of Tapestry, Inc.'s common stock as of December 31, 2025.

BlackRock, Inc. reports 5.1% beneficial ownership in TOAST INC Class A Stock.

BlackRock, Inc. has reported a 6.2% beneficial ownership stake in UL Solutions Inc.'s Class A Stock as of December 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing an 8.3% beneficial ownership in Under Armour Inc. common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in Aclaris Therapeutics, Inc. as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.2% beneficial ownership stake in Akebia Therapeutics Inc. common stock.